OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk
Status:
Not yet recruiting
Trial end date:
2033-01-01
Target enrollment:
Participant gender:
Summary
Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will
identify the patients with a genomic low risk using the multigene-assay (OncoFREE®).
In these, ovarian function suppression with endocrine therapies including either tamoxifen or
aromatase-inhibitors will be administered for 5 years.